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Objective: to verify depressive symptoms and adherence to chemotherapy among women with 
breast cancer who are served by the Pharmacy of the Chemotherapy Center of a university 
hospital. Method: cross-sectional study with quantitative approach conducted with 112 women 
receiving chemotherapy. Structured interviews guided by a script addressing socio-demographic, 
clinical and therapeutic information, the Morisky Test, and the Beck Depression Inventory were 
used to collect data. Results: 12.50% and 1.78% of the patients experienced “moderate” 
and “severe” depression, respectively, while 10.59% did not use antidepressant medication. 
A statistically significant association was found between levels of depression and the use of 
antidepressants. Lack of adherence was identified in 46.43% of the participants. Conclusion: 
these findings show the need to regularly screen for depressive symptoms and for adherence to 
chemotherapy treatment among women with breast cancer, in order to provide early detection 
and appropriate treatment centered on patients, and to improve their quality of life.
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Introduction
Breast cancer is the malignant neoplasia accounting 
for the highest number of deaths among women in 
Brazil and in the world. A total of 52,680 new cases 
were estimated in Brazil for 2012, i.e., an incidence of 
52.5/100,000 women(1).
Physical and psychological changes are evident 
and impactful from the time the diagnosis is revealed 
and, even though efficient treatments are available 
and survival rates have significantly improved in recent 
years, cancer is still seen as a distressful disease with 
a potential risk of death. Patients are faced with the 
imminent loss of a body part highly invested in feminine 
representations and the fear of an incurable disease, 
which results in suffering and stigmatization(2).
Many factors are associated with the triggering 
of psychosocial and physical stress in patients with 
breast cancer: surgery, coadjunvant treatments, fear 
of recurrence and death, bodily changes, reduced 
femininity and sexuality(2). These changes are frequently 
accompanied by depression, a psychiatric morbidity that 
is common during and after treatment of this type of 
cancer(3).
In this regard, the literature shows that depressive 
symptoms are recurrent in patients with clinical diseases, 
including those with breast cancer. These symptoms, 
experienced by about 22% of patients(4), may progress to 
a chronic condition and prevent patients from performing 
daily tasks. In more severe cases, this condition may lead 
to suicide. One study reports that pain and depression 
were associated with the risk of suicide among patients 
with cancer(5). Monitoring patients with the purpose of 
identifying behavioral traits, including suicidal thoughts, 
is essential to grounding both pharmacological and non-
pharmacological approaches(6). 
Even though depression is recurrent among cancer 
patients, it often goes unnoticed, or when a diagnosis 
is reached, the condition is not properly treated. 
Only 35% of the patients are properly diagnosed and 
treated(7). This is a relevant factor, because depression is 
associated with a worse prognosis and higher mortality 
due to cancer(8). 
Cancer patients with depressive symptoms also 
tend to present less adherence to treatments, and 
consequently with a worse prognosis(5). In addition 
to depressive symptoms, the literature shows that 
various factors account for low adherence among cancer 
patients, including adverse effects from medication, 
the need for significant behavioral change, poor 
communication between patients and health workers, 
inefficiency in health services, the complexity of 
therapeutic schemes, patient dissatisfaction with care 
delivery, insufficient social support, and patient beliefs 
concerning treatment, among other factors(9). Non-
adherence to treatment among breast cancer patients is 
associated with worse clinical outcomes, indicating the 
importance of screening.
All the aforementioned aspects point to the 
importance of investigating depressive symptoms and 
adherence to chemotherapy among breast cancer 
patients to optimize treatment and improve patients’ 
quality of life.
Objective
To verify depressive symptoms and adherence to 
chemotherapy among women with breast cancer served 
by the Pharmacy of the Chemotherapy Center of a large 
university hospital.
Method
This analytical, cross-sectional study with a 
quantitative approach was conducted in the Pharmacy of 
the Chemotherapy Center of a large university hospital 
located in the interior of São Paulo, Brazil. This pharmacy 
provides free-of-cost oral and injectable chemotherapy 
medication to patients in follow-up in the facility.
The convenience sample was composed of 
112 patients with a breast cancer diagnosis who 
received their chemotherapy at the pharmacy of the 
Chemotherapy Center from October 2012 to March 2013. 
Inclusion criteria were: having a medical diagnosis of 
breast cancer; having a prescription for chemotherapy 
medication; and being 18 years old or older. All the 
patients who attended the service in the period of data 
collection and met the inclusion criteria were invited to 
participate in the study.
Structured interviewing was the technique used to 
collect data. Interviews were held in a private room in 
the facility and were based on a script composed of three 
parts. The first addressed the patients’ demographic, 
socioeconomic, clinical and therapeutic variables. In 
regard to the medication, their description was based 
on the first level of the Anatomical Therapeutic Chemical 
(ATC) classification system of the WHO (www.whocc.no/
atc_ddd_index).
The second part of the script was composed of 
the Morisky Test(10), which enables identifying patient 
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adherence to medication therapy and assesses behavior 
concerning the daily use of medication. The instrument 
is composed of four questions: Do you sometimes forget 
to take your medicine?; Are you careless at times about 
taking your medicine?; When you feel better, do you 
sometimes stop taking your medicine?; and If you feel 
worse when you take medicine, do you sometimes stop 
taking it?
Adherence was measured using dichotomous 
answers: “No” and “Yes”, to which 0 (zero) and 1 were 
respectively assigned. Hence, 1 was assigned to positive 
answers and 0 to negative answers. With the purpose to 
compare and discuss results, we established criteria to 
classify levels of adherence: more adherent for patients 
who obtained a score of 0 on the Morisky test, and 
less adherent for those who scored from 1 to 4 on the 
instrument.
The script’s third part was intended to identify 
the presence of depressive symptoms in the study 
sample. For that, the Beck Depression Inventory 
was used(11). This instrument consists of a self-report 
scale for symptoms, composed of 21 items with 
different alternatives for answers concerning how the 
individual has felt in the last week, including the date 
upon which the instrument was applied. These items 
correspond to different levels of severity of depressive 
symptoms. The sum of the items’ scores results in an 
overall score that permits establishing the intensity of 
depressive symptoms: “no depression”, “dysphoria”, 
“moderate depression”, and “severe depression”. 
The choice of the cut off point appropriate for each 
level depends on the nature of the sample and the 
study’s objectives. For samples not diagnosed with 
depression, as is the case in this study, scores above 
15 are recommended to detect “dysphoria” and the 
term “depression” is designated for individuals with 
scores above 20.
After the instruments were applied, data related 
to adherence and to the Beck Depression Inventory 
were analyzed using the EpiInfo™ program, version 
3.2, in the public domain (http://www.cdc.gov/
epiinfo). Potential associations between dependent and 
independent variables were verified through Fisher’s 
exact test whenever the frequency of the patients was 
below five. The Chi-square test was used whenever the 
frequency was above five. For that, the variables were 
then dichotomized, adopting a level of significance of α 
= 0.05.
The project was approved by the Institutional 
Review Board at the institution where the study was 
developed (Process HCRP No. 6349/2010) and the 
participants signed free and informed consent forms in 
accordance with Resolution 196/96, Brazilian Council of 
Health.
Results
A total of 112 women aged between 26 and 90 
years old participated in the study. There were a greater 
percentage of married (47.32%) and retired (34.82%) 
women, and homemakers (28.57%).
Most patients undergoing treatment used only 
one chemotherapy medication (94.64%), medication 
classified as L02B- hormone antagonists and related 
agents (98.21%), and had undergone only one surgery 
in their lifetime (58.04%) (Table 1).
Table 1 – Distribution of the study participants according 
to clinical and therapeutic variables. Ribeirão Preto, SP, 
Brazil, 2013
Variables n %
Number of medications 
One medication 106 94.64
More than one medication 6 5.36
ATC Classification
Alkylating agents (L01A) 2 1.78
Antimetabolites (L01B) 1 0.89
Plant alkaloids and other natural products (L01C) 2 1.78
Cytotoxic antibiotics and related substances 
(L01D)
2 1.78
Other anticancer agents (L01X) 1 0.89
Hormones antagonists and related agents (L02B) 110 98.21
Number of surgeries
Up to one surgery 65 58.04
More than one surgery 47 41.96
Time since diagnosis
1 – 30 months 56 50.00
31 – 144 months 56 50.00
Total 112 100.00
The results indicate that 12.50% and 1.78% of 
the patients, respectively, presented “moderate” or 
“severe” depression according to the classification 
of intensity of depressive symptoms recommended 
by the Beck Depression Inventory(11). Because anti-
depressive medication is usually prescribed to patients 
with moderate or severe depression, we opted to 
dichotomize the intensity of depressive symptoms into 
“no depression or with dysphoria” and “moderate or 
severe depression” to present data concerning the use 
of this therapeutic classification. Note that 10.59% 
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of the patients classified with “moderate” or “severe” 
depression did not take anti-depressive medication 
and 25.93% presented depressive symptoms even 
though they were taking antidepressants. Statistically 
significant association was found between the 
intensity of depressive symptoms and the use of anti-
depressants (χ2=0.998; p=0.04). Note that 74.07% 
of the patients using anti-depressants presented no 
depressive symptom or presented only mild symptoms 
(Figure 1).
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Figure 1 – Distribution of the study’s participants 
according to the intensity of depressive symptoms and 
use of anti-depressive medication
Table 2 – Prevalence of depressive symptoms according to demographic, socioeconomic, clinical and therapeutic 
variables. Ribeirão Preto, SP, Brazil, 2013
Variables
Dysphoria and no 
depression Moderate and severe depression Total p
N (%) N (%) N(%)
Age 0.10
Up to 56 years old 45 (80.36) 11 (19.64) 56 (100.00)
57 years old or older 51 (91.07) 05 (8.93) 56 (100.00)
Marital status 0.64
Partner 48 (87.27) 07 (12.73) 55 (100.00)
No partner 48 (84.21) 09 (15.79) 57 (100.00)
Schooling 0.65
Completed middle school 87 (86.14) 14 (13.86) 101 (100.00)
Bachelor’s or graduate studies 09 (81.81) 02 (18.19) 11 (100.00)
Occupation 0.38
With income 64 (83.11) 13 (16.89) 77 (100.00)
No income 32 (91.43) 03 (8.57) 35 (100.00)
Per capita income 0.87
Up to 400 Brazilian Reais 52 (85.25) 09 (14.75) 61 (100.00)
More than 400 Brazilian Reais 44 (86.27) 07 (13.73) 51 (100.00)
Number of dependents 0.17
Up to 3 dependents 75 (88.23) 10 (11.77) 85 (100.00)
More than 3 dependents 21 (77.78) 06 (22.22) 27 (100.00)
Number of surgeries 0.43
Data analysis revealed no statistically significant 
association among intensity of depressive symptoms 
and the demographic, socioeconomic, clinical or the 
therapeutic variables investigated in this study. It is worth 
noting, however, that a higher percentage of moderate to 
severe depression was found among women aged up to 
36 years old (19.64%), with income (16.89%), with more 
than three dependents (22.22%), and among those who 
undergone two or more surgeries (17.39%) (Table 2).
A total of 46.43% of the patients failed to adhere to 
the medication prescribed to treat their cancer. Note that 
5.35% presented “moderate” or “severe” depression. 
Most of the patients without depressive symptoms were 
adherent to medication (Figure 2).
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Figure 2 – Distribution of the study’s participants 
according to the classification of symptoms and 
adherence to chemotherapy treatment
(continue...)
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No significant association was found between 
adherence to chemotherapy and the studied variables 
(p>0.05), though a higher percentage of adherence 
was found among women aged 57 years old or older 
(57.14%), with no partner (56.14%), with income 
(57.14%), and among those whose diagnosis was up to 
12 months prior (70.00%) (Table 3).
Table 3 – Prevalence of adherence to chemotherapy therapy according to demographic, socioeconomic, clinical and 
therapeutic variables. Ribeirão Preto, SP, Brazil, 2013
Variable
Adherent No Adherent Total
p
N (%) N (%) N (%)
Age
Up to 56 years old 27 (48.21) 29 (51.79) 56 (100.00) 0.34
57 years old or older 32 (57.14) 24 (42.86) 56 (100.00)
Marital status
Partner 27 (49.09) 28 (50.91) 55 (100.00) 0.45
No partner 32 (56.14) 25 (43.86) 57 (100.00)
Schooling
Completed middle school 52 (51.49) 49 (48.51) 101 (100.00) 0.53
Bachelor’s or graduate studies 07 (63.64) 04 (36.36) 11 (100.00)
Occupation
With income 44 (57.14) 33 (42.86) 77 (100.00) 0.16
No income 15 (42.86) 20 (57.14) 35 (100.00)
Per capita income
Up to 400 Brazilian Reais 31 (50.82) 30 (49.18) 61 (100.00) 0.66
More than 400 Brazilian Reais 28 (54.90) 23 (45.10) 51 (100.00)
Number of dependents 
Up to 3 dependents 44 (51.76) 41 (48.24) 85 (100.00) 0.73
More than 3 dependents 15 (55.56) 12 (44.44) 27 (100.00)
Number of surgeries
Up to 1 surgery 34 (51.51) 32 (48.49) 66 (100.00) 0.76
More than 2 surgeries 25 (54.35) 21 (45.65) 46 (100.00)
Number of medications
 Up to 1 medication 56 (52.83) 50 (47.17) 106 (100.00) 1.00
 More than 1 medication 03 (50.00) 03 (50.00) 06 (100.00)
Time since diagnosis 0.12
Up to 12 months 14 (70.00) 06 (30.00) 20 (100.00)
From 13 to 36 months 26 (50.00) 26 (50.00) 52 (100.00)
From 37 to 60 months 10 (45.46) 12 (54.54) 22 (100.00)
More than 60 months 09 (50.00) 09 (50.00) 18 (100.00)
Variables
Dysphoria and no 
depression Moderate and severe depression Total p
N (%) N (%) N(%)
Up to one surgery 58 (87.88) 08 (12.12) 66 (100.00)
Two or more surgeries 38 (82.61) 08 (17.39) 46 (100.00)
Number of medications 1.00
Up to one medication 91 (85.85) 15 (14.15) 106 (100.00)
More than one medication 05 (83.33) 01(16.67) 06 (100.00)
Time since diagnosis 0.80
Up to 12 months 17 (85.00) 03 (15.00) 20 (100.00)
From 13 to 36 months 45 (83.33) 09 (16.67) 54 (100.00)
From 37 to 60 months 18 (85.71) 03 (14.29) 21 (100.00)
More than 60 months 16 (94.12) 01 (5.88) 17 (100.00)
Table 2 - continuation
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Discussion
This study investigated depressive symptoms and 
adherence to chemotherapy treatment among women 
with breast cancer. We verified that 12.50% and 1.78% 
of the patients presented “moderate” or “severe” 
depression, respectively, according to the classification 
adopted by Beck(11). The literature shows that women 
with breast cancer undergoing chemotherapy present 
a higher rate of depression(12). The factors contributing 
to depression include sleep disorders, menopausal 
symptoms, nausea, and pain caused by the high levels 
of proinflammatory cytokines, due to the tissue damage 
that results from chemotherapy and radiotherapy(13). It 
is important to keep in mind that the rapid decrease 
of estrogen during chemotherapy also favors depressive 
symptomatology, because this hormone increases the 
brain’s sensitivity to serotonin(14).
Depression is a chronic condition associated with high 
levels of functional impairment, negative development 
of concomitant clinical diseases, severe psychological 
and physical distress, which may result in suicide(5). 
An alarming fact in this context is that 10.59% of the 
patients who did not use anti-depressant medication 
presented “moderate” to “severe” depression.
Note that even taking medication, 25.93% of the 
patients still presented depressive symptoms. A possible 
explanation for this finding is the time antidepressant 
medication has been in use, that is, less than the time 
necessary to obtain therapeutic results, a variable 
that was not investigated in this study. The literature 
shows, however, that about 30% to 50% of depressive 
conditions do not satisfactorily respond to the first 
treatment even when it is properly implemented, 
regardless of the medication prescribed(15). A study that 
investigated some depressive symptoms in a sample of 
patients with a diagnosis of depression and in continuous 
use of medication reports that 42% of the individuals 
still experience severe symptoms (16).
The described aspects reveal the importance 
of using psychosocial interventions, in addition to 
medication therapy, when treating depression for 
patients to achieve complete recovery and improved 
quality of life(17). In this case, psychotherapy, with its 
different approaches, can be used either as the primary 
treatment or as an adjuvant to pharmacotherapy, 
especially when considering the characteristics of the 
treatment delivered to cancer patients.
Statistical significance between intensity of 
depressive symptoms and the use of antidepressant 
medication was found. Most patients (74.07%) 
using antidepressants did not experience depressive 
symptoms or only experienced mild symptoms. The 
importance of antidepressants for this population is 
also related to its efficacy in treating other symptoms 
frequently associated with breast cancer, including 
fatigue, difficulties sleeping and hot flashes(18). 
In regard to the relationship between depressive 
symptoms and the variables investigated in this study, 
we note that the highest percentages of “moderate” and 
“severe” depression were found among women up to 
the age of 56 years, but there is no consensus in the 
literature of how age is related to depression. One study, 
however, shows intense concern on the part of young 
women with breast cancer in regard to chemotherapy 
because it reduces the production of female hormones, 
which may result in early menopause with a consequent 
infertility, in addition to the difficulty dealing with 
the psychological stress related to the partial or total 
removal of breasts(6).
This study reveals that 46.3% of the patients did 
not adhere to the chemotherapy medication prescribed 
to treat their cancer. This percentage is high considering 
the consequences of such a behavior, because lower 
adherence levels are associated with increased risk of 
death(19).
One study reveals that non-adherence to tamoxifen 
was associated with lower rates of survival, free of the 
disease(20). This is relevant information for this study 
because most of the investigated patients (98.21%) used 
medications classified as L02B– hormone antagonist 
and related agents, and tamoxifen was the medication 
most frequently prescribed. Tamoxifen is an estrogen 
hormone adjuvant used for more than 25 years to treat 
women with breast cancer with proven efficiency for the 
reduction of mortality and in preventing recurrences. The 
use of tamoxifen, compared to no treatment, reduces 
the risk of recurrence for about 15 years(21).
The factors usually indicated as those contributing 
to non-adherence in breast cancer patients include the 
therapy’s adverse effects. Hormone therapy, including 
tamoxifen, may cause hot flashes, fluid retention, 
bleeding, skin rashes, vaginal itching and dryness, 
the risk of endometrial cancer, joint pain, or deep vein 
thrombosis, among other(22).
No statistically significant association was 
found between adherence to chemotherapy and the 
studied variables. Note, however, that higher levels of 
adherence were found among women 57 years or older 
and those with no partners. In regard to age, one study 
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corroborates this study’s results, as it reports higher 
adherence among older women(9). Nonetheless, there is 
no consensus in the literature in regard to this aspect. 
The higher level of adherence among patients without 
a partner conflicts with results in the literature, which 
suggests that the presence of a partner is associated 
with higher levels of adherence(23), thus, further research 
is needed to investigate the relationship between these 
variables.
 A total of 5.35% of the patients who did not 
adhere to medication experienced moderate or severe 
depression. There is evidence that depression may be 
associated with non-adherence to treatment(7). Even 
though antidepressant medication is required for these 
patients, the medication to be prescribed to patients 
has to be carefully chosen. Selective serotonin reuptake 
inhibitors (SSRIs) are widely used; they may, however, 
inhibit cytochrome P450 2D6, necessary to activate 
tamoxifen, interfering in the efficiency of this medication 
for the prevention of breast cancer recurrence. It is 
currently believed that Citalopram, and possibly other 
SSRIs with lower potency, may be prescribed to these 
patients without negatively affecting the result of the 
adjuvant therapy with tamoxifen(24). The possibility 
of such a pharmacological intervention suggests that 
oncologists and psychiatrics need to work together.
It is important to note that this study’s results should 
be considered while bearing in mind its methodological 
limitations: the use of a convenience sample and the 
fact the study was conducted in a single facility with 
outpatients, which limits the generalization of results to 
other groups. 
Conclusion
This study investigated depressive symptoms and 
adherence to chemotherapy treatment among women 
with breast cancer. A high percentage of non-adherent 
patients with intense depressive symptoms such as 
“moderate” and “severe” depression was found.
The identification of women with depressive 
symptoms, despite the use of antidepressants, is 
an important finding given the influence of such 
symptoms, both on treatment adherence and on the 
progression of cancer. This result indicates that other 
therapeutic modalities are required in addition to a 
psychopharmacological approach.
These results also show the importance of evaluating 
the antidepressant medication most appropriate to 
the patient while taking into account the anticancer 
treatment she will undergo, because the class of 
antidepressants may be related both to the improvement 
of symptoms attributed to the disease and to the 
chemotherapy treatment, such as its reduced efficiency 
with a consequent reduced rate of survival free of the 
disease. Therefore, for the assessment and treatment 
of these patients to be effective, it is imperative that 
oncological and psychiatric staff work together.
Note that in addition to considering the patients, 
their social support network should also be taken into 
account, so that family members and intimate partners 
are involved in the process of adapting to the treatment 
with the help of a qualified, multi-professional team. 
Nurses, as members of these teams, have a key role 
in the implementation of psychosocial strategies for 
individual or groups, directed to the optimization of the 
treatment of depressive symptoms and the promotion of 
adherence to chemotherapy treatment. 
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